MX366765B - Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple. - Google Patents

Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.

Info

Publication number
MX366765B
MX366765B MX2015009818A MX2015009818A MX366765B MX 366765 B MX366765 B MX 366765B MX 2015009818 A MX2015009818 A MX 2015009818A MX 2015009818 A MX2015009818 A MX 2015009818A MX 366765 B MX366765 B MX 366765B
Authority
MX
Mexico
Prior art keywords
ppar
agonists
treatment
multiple sclerosis
int131
Prior art date
Application number
MX2015009818A
Other languages
English (en)
Other versions
MX2015009818A (es
Inventor
David Weinstein
Original Assignee
Intekrin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics Inc filed Critical Intekrin Therapeutics Inc
Publication of MX2015009818A publication Critical patent/MX2015009818A/es
Publication of MX366765B publication Critical patent/MX366765B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para tratar esclerosis múltiple (EM) con agonistas de PPAR?, y en particular, con el compuesto de fórmula (I) conocido como INT131: (ver Fórmula).
MX2015009818A 2013-01-30 2014-01-23 Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple. MX366765B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361758641P 2013-01-30 2013-01-30
PCT/US2014/012656 WO2014120538A1 (en) 2013-01-30 2014-01-23 PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS

Publications (2)

Publication Number Publication Date
MX2015009818A MX2015009818A (es) 2015-10-29
MX366765B true MX366765B (es) 2019-07-23

Family

ID=51223587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009818A MX366765B (es) 2013-01-30 2014-01-23 Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.

Country Status (15)

Country Link
US (3) US9061020B2 (es)
EP (1) EP2950798B1 (es)
JP (3) JP5989921B2 (es)
KR (2) KR102056756B1 (es)
CN (1) CN105228622B (es)
AU (1) AU2014212740B2 (es)
BR (1) BR112015018048A2 (es)
CA (1) CA2899187C (es)
EA (2) EA029216B1 (es)
ES (1) ES2883141T3 (es)
HK (1) HK1218510A1 (es)
IL (2) IL240051A (es)
MX (1) MX366765B (es)
SG (2) SG10201805896SA (es)
WO (1) WO2014120538A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
KR102056756B1 (ko) * 2013-01-30 2019-12-17 인테크린 테라퓨틱스, 아이엔씨. 다발성 경화증의 치료를 위한 PPARγ 작용제
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CA3034258A1 (en) * 2016-08-18 2018-02-22 Intekrin Therapeutics, Inc. Ppar.gamma. agonist for treatment of blood cancers
AU2017313842A1 (en) * 2016-08-18 2019-03-07 Intekrin Therapeutics, Inc. PPARgamma AGONIST FOR TREATMENT OF BONE DISORDERS
SG10202102198RA (en) * 2016-09-13 2021-04-29 Intekrin Therapeutics Inc Treatment of multiple sclerosis with chs-131
AU2018249822A1 (en) * 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
EA201992364A1 (ru) * 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
WO2009007673A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
WO2009097997A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
WO2012040082A2 (en) * 2010-09-21 2012-03-29 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
KR102056756B1 (ko) * 2013-01-30 2019-12-17 인테크린 테라퓨틱스, 아이엔씨. 다발성 경화증의 치료를 위한 PPARγ 작용제

Also Published As

Publication number Publication date
KR102056756B1 (ko) 2019-12-17
CN105228622A (zh) 2016-01-06
US9539249B2 (en) 2017-01-10
MX2015009818A (es) 2015-10-29
US9061020B2 (en) 2015-06-23
JP2016506956A (ja) 2016-03-07
SG10201805896SA (en) 2018-08-30
US20170143687A1 (en) 2017-05-25
JP6466540B2 (ja) 2019-02-06
IL248594B (en) 2021-10-31
JP2017014251A (ja) 2017-01-19
SG11201505944QA (en) 2015-08-28
KR20150133182A (ko) 2015-11-27
JP2018039817A (ja) 2018-03-15
KR20160137653A (ko) 2016-11-30
BR112015018048A2 (pt) 2020-01-28
EP2950798A1 (en) 2015-12-09
AU2014212740A1 (en) 2015-08-13
JP5989921B2 (ja) 2016-09-07
CA2899187A1 (en) 2014-08-07
EP2950798B1 (en) 2021-05-12
IL240051A (en) 2016-11-30
AU2014212740B2 (en) 2015-12-24
ES2883141T3 (es) 2021-12-07
EP2950798A4 (en) 2016-06-29
HK1218510A1 (zh) 2017-02-24
CN105228622B (zh) 2017-09-22
EA201591399A1 (ru) 2015-12-30
JP6224189B2 (ja) 2017-11-01
IL248594A0 (en) 2016-12-29
WO2014120538A1 (en) 2014-08-07
EA029216B1 (ru) 2018-02-28
IL240051A0 (en) 2015-09-24
US9867816B2 (en) 2018-01-16
EA201792096A2 (ru) 2018-01-31
US20150238478A1 (en) 2015-08-27
US20140213612A1 (en) 2014-07-31
EA201792096A3 (ru) 2018-05-31
CA2899187C (en) 2016-06-07

Similar Documents

Publication Publication Date Title
MX366765B (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12015502659A1 (en) Surface treatment compositions comprising photochromic dyes
MY184733A (en) Pyrimidine fgfr4 inhibitors
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
MX2020002544A (es) Sales de glicopirrolato.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
IN2014DN11078A (es)
WO2014146111A3 (en) Analgesic compounds and methods of use
EA201591709A1 (ru) 5-бром-индирубины
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
MX2016005219A (es) Tinturas acidas, proceso para su produccion y su uso.
MX2016005220A (es) Tinturas acidas, proceso para su produccion y su uso.
UA91886U (uk) 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол
UA86158U (en) Antibacterial agent
UA86107U (ru) Пиперазиния 1-н-бутилтеобромин-8-илтиоацетат, который проявляет диуретическое действие
MX2016005221A (es) Tinturas acidas, proceso para su produccion y su uso.
UA80877U (en) 2-hydroxyethyl-1,3,4-trimethylcyclohex-3-ene-1-carboxylate
UA91089U (uk) Застосування препарату "біоглобін-у" як препарату для корекції гіпотиреоїдних станів в експерименті
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства

Legal Events

Date Code Title Description
FG Grant or registration